USX:CTSO - Cytosorbents Corp (USD 6.59) Cytosorbents Corp
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance

USD 6.59    -0.310 (-4.49%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


9 Apr 2020

Day Change: -0.310 (-4.49%)

52 Wk Range: 3.49 - 8.1

Day's Range: 6.5 - 6.97

Last Volume: 435,701

Current Yield: 0%

Projected Yield: 0%

Open: USD 6.89

9 Apr 2020

Metric CTSO S.Median
Beta 0.83 0.84
VaR 40.16 25.23
E.Shortfall 54.5 45.03
Liquidity 475.06K 95.2K


9 Apr 2020

PE: -10.432

Market Cap: 216.2M

Price Over Book: 32.1

Price Over Sales: 9.16

Return On Assets: -72.2%

Return On Equity: -307.7%

Price Over NAV: [Friends Only]


CEO: Phillip P. Chan

Headquarters: Monmouth Junction

Employees: 125

Sector: Health Technology

Industry: Medical Specialties

Useful Links


CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. The company also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, it is developing CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, CytoSorbents Corporation is developing BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. CytoSorbents Corporation was founded in 1997 and is headquartered in Monmouth Junction, New Jersey.